The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the ‘unexplainable’

Michele Basso, Vincenzo Dadduzio, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Mariantonietta Di Salvatore, Armando Orlandi, Valeria Zurlo, Vincenzo Di Noia, Carlo Barone
  • Personalized Medicine, June 2018, Future Medicine
  • DOI: 10.2217/pme-2017-0082

An idea on the interference between oxaliplatin and anti-EGFR therapies

What is it about?

When oxaliplatin has been combined with anti-EGFR therapies, a detrimental effect has been observed in KRAS mutated patients. Even for wild-type patients, anti-EGFRs seem not to be the best partner for oxaliplatin. In this paper we describe our hypothesis concerning this supposed negative interference.

Why is it important?

This paper, with an original point of view, gives reason both of detrimental effect observed in KRAS mutated and also of the puzzling results observed when oxaliplatin has been combined with anti-EGFR therapies even in wild type RAS patients. Moreover our point of view seems to be able to explain some particular issues, such as the detrimental effect observed in the microscopic disease of wild-type patients.

Perspectives

Michele Basso (Author)
Fondazione Policlinico Universitario "A Gemelli" IRCCS

The hypothesis we propose in this paper, if confirmed, wil offer the possibility of further personalized therapies in patients affected by advanced colorectal cancer, based on the rate of membrane EGFR expression.

The following have contributed to this page: Michele Basso